Is Ashwagandha appropriate for treating mild‑moderate stress, anxiety, or fatigue in healthy adults, and what dosing and contraindications should be considered?

Ashwagandha for Stress, Anxiety, and Fatigue in Healthy Adults

Ashwagandha can be recommended for healthy adults with mild-to-moderate stress, anxiety, or fatigue at doses of 125-500 mg daily, though it is not included in major oncology guidelines and carries important contraindications.

Evidence Quality and Context

The available evidence comes primarily from research studies rather than major clinical guidelines. Notably, the 2024 ASCO-Society for Integrative Oncology guidelines for fatigue management 1 and the 2023 ASCO guidelines for anxiety/depression 2 do not include ashwagandha in their recommendations, instead focusing on American ginseng (Panax quinquefolius) for cancer-related fatigue and psychological interventions for anxiety/depression. This absence from major guidelines is significant and suggests ashwagandha lacks the robust evidence base of other interventions in clinical populations.

Efficacy Evidence

Stress and Anxiety

Multiple meta-analyses demonstrate significant benefits:

• 2024 meta-analysis (9 RCTs, 558 patients) showed significant improvements in Perceived Stress Scale (PSS) scores (MD = -4.72), Hamilton Anxiety Scale scores (MD = -2.19), and serum cortisol levels (MD = -2.58) compared to placebo 3

• 2022 meta-analysis (12 RCTs, 1,002 participants) found substantial reductions in both anxiety (SMD: -1.55) and stress (SMD: -1.75), though the certainty of evidence was rated as low 4

• Dose-response analysis suggested optimal effects at 300-600 mg/day for stress 4

Fatigue

• 2024 RCT (131 adults) demonstrated that even the lowest dose of 125 mg/day significantly reduced chronic stress in a dose-dependent manner over 8 weeks 5

• 2023 RCT showed significant reduction in fatigue symptoms (p = 0.016) and increased heart rate variability (p = 0.003) with 200 mg twice daily, though stress improvements were not significantly different from placebo 6

Specific Formulations

• High-withanolide formulations (35% withanolide glycosides) at 60-120 mg daily showed dramatic reductions: 59% decrease in anxiety scores, 66-67% decrease in cortisol, and 22-33% increase in testosterone 7

Recommended Dosing

Based on FDA labeling 8 and research evidence:

• Standard dose: 125-500 mg daily, typically divided into two doses
• Timing: Morning and midday dosing preferred to avoid sleep disruption
• Duration: 8-12 weeks for optimal effects, based on trial data 3, 4, 5
• High-potency extracts: 60-120 mg daily if using standardized extracts with 35% withanolide glycosides 7

Critical Contraindications and Safety Concerns

Absolute contraindications per FDA labeling 8:

• Pregnancy
• Breastfeeding
• Children under 18 years

Emerging safety concerns from recent critical review 9:

• Hepatotoxicity: Liver toxicity reported with prolonged or excessive use
• Thyrotoxicosis: Endocrine-modulating effects can trigger thyroid dysfunction
• Adrenal suppression: Potential HPA axis disruption with chronic use
• Drug interactions: Metabolized via cytochrome P450 enzymes, creating potential for interactions with medications
• Immune hypersensitivity: Allergic reactions possible
• Gastrointestinal effects: Common mild-to-moderate adverse events

Clinical Algorithm

Step 1: Screen for contraindications

• Pregnant/nursing? → Do not use
• Under 18 years? → Do not use
• Liver disease or elevated liver enzymes? → Avoid or use with extreme caution
• Thyroid disorders? → Avoid or monitor closely

Step 2: If appropriate candidate, start low

• Begin with 125 mg daily (or 60 mg if using high-potency extract)
• Take in morning to assess tolerance

Step 3: Titrate based on response

• If tolerated after 1-2 weeks, increase to 125 mg twice daily
• Maximum dose: 500 mg daily (standard extract) or 120 mg daily (high-potency)

Step 4: Monitor and reassess

• Evaluate response at 4-8 weeks
• If no improvement by 8 weeks, discontinue
• Monitor for adverse effects, particularly GI symptoms or fatigue worsening

Important Caveats

1. Not first-line for clinical populations: Major guidelines recommend psychological interventions (CBT, mindfulness) and exercise as first-line for stress/anxiety 2, not supplements

2. Evidence quality limitations: Despite positive meta-analyses, the certainty of evidence remains low 4, and ashwagandha is notably absent from major clinical guidelines

3. Standardization issues: Withanolide content varies widely between products; choose standardized extracts

4. Long-term safety unknown: Most trials are 8-12 weeks; safety beyond this timeframe is unclear 9

5. Population-specific: Most evidence is in healthy adults with self-reported stress, not diagnosed anxiety disorders or clinical depression

6. Hepatotoxicity risk: Recent critical reviews emphasize liver toxicity concerns, particularly with prolonged use 9—consider baseline and periodic liver function monitoring if using long-term

For patients with moderate-to-severe anxiety or depression, prioritize evidence-based psychological interventions (CBT, behavioral activation) and consider pharmacotherapy over supplements 2.